Ferrer Global Corp buys 87-year-old Spanish drugmaker VIR
What's the deal? Ferrer Global Corp., the Florida-based group founded by pulmonologist Gustavo Ferrer, has acquired Spanish pharmaceutical company VIRDealroom has a profile for this one. Try Dealroom →, it announced on October 21. Terms were not disclosed. VIR, based in Alcorcón near Madrid, employs about 100 people, holds more than 260 registered medicines, and operates in over 40 countries.
What changes? The company will be renamed VIR by Dr. Ferrer. The deal adds drug development and manufacturing to a group that previously focused on clinical services and digital health technology.
What's the endgame? Ferrer, which also runs The Moxie Health GroupDealroom has a profile for this one. Try Dealroom → and the MoxieLink digital health platform, wants to link patient needs directly to the development, manufacturing, and supply of treatments. The initial focus is respiratory medicine, including respiratory therapies, nasal drug delivery systems, and technologies to treat patients outside traditional hospital settings.
Why now? The acquisition follows a five-year relationship that began at CPHI, an international pharmaceutical industry event, where Ferrer met VIR's management while seeking manufacturing partners for nasal drug delivery. Those contacts grew into a collaboration on pharmaceutical development and patented drug-delivery technologies.
What they said: "We didn't come to VIR simply to acquire a factory. We came to build on 87 years of history and give that legacy a new future," Ferrer said in a statement (translated from Spanish).
The signal: The group plans to turn Madrid into a strategic hub for pharmaceutical manufacturing, research and development, and collaboration across Europe, the US, and the Americas. The move signals how vertically integrated health groups are folding development and production in-house to control the path from diagnosis to treatment.
Read more: diariodesevilla.es
Image credit: Generated with Gemini
